KR102534457B1 - 방사선 피부염의 치료를 위한 국소 BRaF 억제제 조성물의 용도 - Google Patents

방사선 피부염의 치료를 위한 국소 BRaF 억제제 조성물의 용도 Download PDF

Info

Publication number
KR102534457B1
KR102534457B1 KR1020217029012A KR20217029012A KR102534457B1 KR 102534457 B1 KR102534457 B1 KR 102534457B1 KR 1020217029012 A KR1020217029012 A KR 1020217029012A KR 20217029012 A KR20217029012 A KR 20217029012A KR 102534457 B1 KR102534457 B1 KR 102534457B1
Authority
KR
South Korea
Prior art keywords
composition
grade
radiation
rtog
adverse events
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020217029012A
Other languages
English (en)
Korean (ko)
Other versions
KR20210126665A (ko
Inventor
노아 쉘라슈
노아 로웬턴-스파이어
Original Assignee
루트리스 파마 엘티디.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 루트리스 파마 엘티디. filed Critical 루트리스 파마 엘티디.
Publication of KR20210126665A publication Critical patent/KR20210126665A/ko
Application granted granted Critical
Publication of KR102534457B1 publication Critical patent/KR102534457B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020217029012A 2019-02-12 2020-02-11 방사선 피부염의 치료를 위한 국소 BRaF 억제제 조성물의 용도 Active KR102534457B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962804235P 2019-02-12 2019-02-12
US62/804,235 2019-02-12
PCT/IB2020/051073 WO2020165755A1 (en) 2019-02-12 2020-02-11 Use of topical braf inhibitor compositions for treatment of radiation dermatitis

Publications (2)

Publication Number Publication Date
KR20210126665A KR20210126665A (ko) 2021-10-20
KR102534457B1 true KR102534457B1 (ko) 2023-05-18

Family

ID=72044789

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217029012A Active KR102534457B1 (ko) 2019-02-12 2020-02-11 방사선 피부염의 치료를 위한 국소 BRaF 억제제 조성물의 용도

Country Status (17)

Country Link
US (1) US11439648B2 (https=)
EP (1) EP3923911B1 (https=)
JP (1) JP2022519675A (https=)
KR (1) KR102534457B1 (https=)
CN (1) CN113382717A (https=)
AU (1) AU2020220895B9 (https=)
BR (1) BR112021015137A2 (https=)
CA (1) CA3127175C (https=)
ES (1) ES2952251T3 (https=)
HR (1) HRP20231241T1 (https=)
HU (1) HUE063091T2 (https=)
IL (1) IL285560B2 (https=)
MX (1) MX2021009535A (https=)
PL (1) PL3923911T3 (https=)
RS (1) RS64618B1 (https=)
WO (1) WO2020165755A1 (https=)
ZA (1) ZA202106581B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116669739A (zh) * 2020-12-24 2023-08-29 鲁特里斯制药有限公司 用于治疗egfr下游效应物诱导的反应的局部braf抑制剂组合物
MX2024000227A (es) * 2021-07-02 2024-04-16 Lutris Pharma Ltd Uso de isoquinolina-1,5-diaminas para la curacion de heridas.
WO2023051685A1 (zh) * 2021-09-30 2023-04-06 北京大学 一种对红系前体细胞或成红细胞进行扩增的方法及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170100345A1 (en) * 2014-05-06 2017-04-13 The Regents Of The University Of California Wound healing using braf inhibitors
US20180369247A1 (en) 2016-03-10 2018-12-27 Lutris Pharma Ltd. Use of braf inhibitors for treating cutaneous reactions

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5753612A (en) 1992-10-27 1998-05-19 Yissum Research Development Co. Of The Hebrew University Of Jerusalem Pharmaceutical composition and method for inhibiting hair growth by administration of activin or activin agonists
US7989461B2 (en) 2005-12-23 2011-08-02 Amgen Inc. Substituted quinazolinamine compounds for the treatment of cancer
US8557830B2 (en) 2007-06-07 2013-10-15 Amgen Inc. RAF kinase modulators and methods of use
EP3147281A1 (en) * 2008-03-17 2017-03-29 Ambit Biosciences Corporation Quinazoline derivatives as raf kinase modulators and methods of use thereof
WO2011117381A1 (en) * 2010-03-26 2011-09-29 Boehringer Ingelheim International Gmbh B-raf kinase inhibitors
US20130226549A1 (en) 2012-02-27 2013-08-29 Yufeng J. Tseng Structure-based fragment hopping for lead optimization and improvement in synthetic accessibility
KR20140011780A (ko) 2012-07-19 2014-01-29 한미약품 주식회사 단백질 키나아제 저해활성을 갖는 이소퀴놀린-5-카복스아미드 유도체
JP6912667B2 (ja) * 2017-07-29 2021-08-04 ルトリス ファーマ エル ティー ディー． 新規なｂｒａｆ阻害剤および皮膚反応を治療するためのその使用
WO2019032717A1 (en) * 2017-08-08 2019-02-14 Memorial Sloan Kettering Cancer Center USE OF BRAF INHIBITORS FOR TREATING SKIN REACTIONS CAUSED BY TREATMENT WITH MEK INHIBITOR

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170100345A1 (en) * 2014-05-06 2017-04-13 The Regents Of The University Of California Wound healing using braf inhibitors
US20180369247A1 (en) 2016-03-10 2018-12-27 Lutris Pharma Ltd. Use of braf inhibitors for treating cutaneous reactions

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Int J Radiat Oncol Biol Phys, 2016 Jun 1;95(2):632-46.

Also Published As

Publication number Publication date
WO2020165755A1 (en) 2020-08-20
PL3923911T3 (pl) 2023-12-27
ES2952251T3 (es) 2023-10-30
US20210346389A1 (en) 2021-11-11
BR112021015137A2 (pt) 2021-09-28
HRP20231241T1 (hr) 2024-02-16
EP3923911A4 (en) 2022-11-09
HUE063091T2 (hu) 2024-01-28
CN113382717A (zh) 2021-09-10
EP3923911B1 (en) 2023-07-12
JP2022519675A (ja) 2022-03-24
ZA202106581B (en) 2022-09-28
IL285560B2 (en) 2024-04-01
CA3127175C (en) 2023-06-27
AU2020220895A1 (en) 2021-08-12
CA3127175A1 (en) 2020-08-20
RS64618B1 (sr) 2023-10-31
AU2020220895B2 (en) 2022-11-17
AU2020220895B9 (en) 2023-02-02
IL285560A (en) 2021-09-30
IL285560B1 (en) 2023-12-01
KR20210126665A (ko) 2021-10-20
EP3923911A1 (en) 2021-12-22
MX2021009535A (es) 2022-10-10
US11439648B2 (en) 2022-09-13
EP3923911C0 (en) 2023-07-12

Similar Documents

Publication Publication Date Title
CA2301009C (en) Skin care compositions and use
US11439648B2 (en) Use of topical BRAF inhibitor compositions for treatment of radiation dermatitis
CN106659713B (zh) 外用组合物
BR112012001491B1 (pt) Preparação terapêutica para tratar dermatite e uso de uma preparação terapêutica
JP5604792B2 (ja) 外用医薬組成物
KR20220136979A (ko) 콜히친을 포함하는 알레르기성 피부 질환 또는 피부 소양증 치료용 조성물
KR20160098491A (ko) 베르베린 제형 및 이의 용도
KR20150047505A (ko) 건선 치료용 조성물
KR20230139402A (ko) 염증성 피부 증후군을 치료하는 약제학적인 용도의 화장품 조성물
WO2017129108A1 (zh) 一种用于治疗皮肤病的硅凝胶
RU2812708C2 (ru) Применение композиций на основе ингибитора braf для наружного применения для лечения лучевого дерматита
KR20110006890A (ko) 필라그린 생성촉진을 위한 조성물
JP5460766B2 (ja) 外用医薬組成物
JP2008069109A (ja) 外用医薬組成物
US20250114362A1 (en) Methods and compositions for treatment of cutaneous proliferative disorders and other skin conditions
EP3624772B1 (en) Composition for the treatment of forms of skin inflammation
HK1261649B (zh) 抗皮肤过敏的化妆品组合物
WO2005099731A1 (ja) 生薬由来の抗菌剤及びこれを含有する外用組成物
JP2015057377A (ja) アトピー性皮膚炎抑制剤
PL211459B1 (pl) Zastosowanie czwartorzędowych soli pirydyniowych oraz preparat farmaceutyczny zawierający czwartorzędowe sole pirydyniowe
HK1231396B (zh) 外用组合物

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
A302 Request for accelerated examination
AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PA0302 Request for accelerated examination

St.27 status event code: A-1-2-D10-D17-exm-PA0302

St.27 status event code: A-1-2-D10-D16-exm-PA0302

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601